GTC Biotherapeutics (fka GTCB)

[keitern]

Thanks for the clarification. When do the added production costs (LEO EU supply) kick in and do we expect a ramping up in demand over time or flat?

As to valuation, I guess the company would be worth roughly 50M-100M based on Atryn EU sales exclusively which is not far off today's valuation. It is strange that "the rest" is almost completely discounted by the street.